Latest Period
Q2 2026
Security Snapshot
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) Institutional Ownership
CUSIP: 40637H109
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
668
Shares (Excl. Options)
123,170,995
Price
$78.27
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- HALO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 123,170,995
- Total 13F value
- $9,615,134,804
- Portfolio coverage rank
- 0.01%
- Share change
- +2,467,168
- Value change
- +$217,786,099
- Number of holders
- 668
- Shares outstanding
- 118,494,184
- SEC-reported price per share
- $101.79
- Insider filing price
- $101.79
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- HALO - HALOZYME THERAPEUTICS, INC. - Common Stock is tracked under CUSIP 40637H109.
- 668 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 635 to 668 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $7,783,770,594 to $9,615,134,804.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 668 institutions filings for Q2 2026.
Security key
40637H109
Latest holder period
Q2 2026
13F holders
668
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
HALO full holder history
HALOZYME THERAPEUTICS, INC. SEC filings
HALOZYME THERAPEUTICS, INC. company facts
HALOZYME THERAPEUTICS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 40637H109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
HALO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | -22% | $656,091,846 | -$183,727,565 | 12,612,300 | -22% | BlackRock, Inc. | 30 Jun 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $398,996,343 | 6,173,547 | Vanguard Capital Management | 31 Mar 2026 | |||
| STATE STREET CORP | 4.9% | $358,640,665 | 6,053,007 | STATE STREET CORPORATION | 31 Mar 2025 |
As of 30 Jun 2026, 668 institutional investors reported holding 123,170,995 shares of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO). This represents 104% of the company’s total 118,494,184 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
60%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | 13,271,095 | +0.05% | 0.02% | $1,038,728,610 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 5,351,312 | +1.5% | 0.01% | $418,847,190 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5% | 5,299,008 | +0.95% | 0.02% | $414,753,356 |
| STATE STREET CORP | 4.4% | 5,179,434 | +4.9% | 0.01% | $405,379,779 |
| Invesco Ltd. | 2.7% | 3,177,997 | -21% | 0.02% | $248,741,825 |
| MORGAN STANLEY | 2.4% | 2,832,594 | +11% | 0.01% | $221,707,309 |
| Boston Partners | 2.3% | 2,773,568 | +3.3% | 0.19% | $216,820,544 |
| BANK OF AMERICA CORP /DE/ | 2.3% | 2,740,561 | -5.9% | 0.01% | $214,503,722 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 2,519,951 | +0.57% | 0.01% | $197,281,725 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.1% | 2,511,050 | -0.59% | 0.59% | $196,539,884 |
| SNYDER CAPITAL MANAGEMENT L P | 2% | 2,396,101 | +3.1% | 3.2% | $187,542,825 |
| DIMENSIONAL FUND ADVISORS LP | 1.8% | 2,089,567 | +0.47% | 0.03% | $163,542,164 |
| D. E. Shaw & Co., Inc. | 1.7% | 2,006,479 | +7.4% | 0.1% | $157,047,112 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 1.6% | 1,938,035 | +181% | 0.56% | $151,690,000 |
| ROYAL LONDON ASSET MANAGEMENT LTD | 1.5% | 1,810,815 | +12% | 0.26% | $141,732,491 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.4% | 1,704,623 | -11% | 0.06% | $133,420,842 |
| ALLIANCEBERNSTEIN L.P. | 1.4% | 1,696,538 | -2.3% | 0.04% | $109,647,251 |
| TWO SIGMA INVESTMENTS, LP | 1.4% | 1,653,285 | +4.3% | 0.1% | $129,402,617 |
| UBS Group AG | 1.3% | 1,492,224 | +63% | 0.02% | $116,796,372 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1.3% | 1,491,004 | +1.8% | 0.32% | $116,700,910 |
| NORGES BANK | 1.3% | 1,483,648 | 0.01% | $116,125,129 | |
| FIRST TRUST ADVISORS LP | 1.2% | 1,417,063 | -4.4% | 0.07% | $110,913,469 |
| LSV ASSET MANAGEMENT | 1.2% | 1,410,257 | +2.8% | 0.2% | $110,381,000 |
| Stephens Investment Management Group LLC | 1.2% | 1,392,819 | +14% | 1.2% | $109,015,943 |
| WELLS FARGO & COMPANY/MN | 1.2% | 1,390,428 | -9.5% | 0.02% | $108,828,836 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 123,170,995 | $9,615,134,804 | +$217,786,099 | $78.27 | 668 |
| 2026 Q1 | 120,401,446 | $7,783,770,594 | -$154,100,826 | $64.63 | 635 |
| 2025 Q4 | 123,171,269 | $8,286,734,452 | +$134,473,632 | $67.30 | 613 |
| 2025 Q3 | 119,220,823 | $8,742,315,256 | +$226,173,219 | $73.34 | 596 |
| 2025 Q2 | 116,352,424 | $6,053,937,391 | -$203,145,554 | $52.02 | 541 |
| 2025 Q1 | 120,489,904 | $7,687,315,257 | -$91,368,957 | $63.81 | 543 |
| 2024 Q4 | 122,458,776 | $5,856,815,335 | -$193,231,691 | $47.81 | 500 |
| 2024 Q3 | 125,205,134 | $7,161,621,740 | +$188,148,727 | $57.24 | 503 |
| 2024 Q2 | 122,186,529 | $6,397,611,292 | -$49,238,862 | $52.36 | 449 |
| 2024 Q1 | 123,583,310 | $5,026,636,534 | -$29,500,183 | $40.68 | 409 |
| 2023 Q4 | 124,680,353 | $4,614,991,205 | +$45,612,024 | $36.96 | 409 |
| 2023 Q3 | 123,213,224 | $4,707,973,255 | -$3,726,561 | $38.20 | 389 |
| 2023 Q2 | 123,025,101 | $4,439,170,134 | -$50,628,033 | $36.07 | 368 |
| 2023 Q1 | 124,051,427 | $4,736,116,144 | -$286,882,621 | $38.19 | 381 |
| 2022 Q4 | 129,468,465 | $7,364,542,615 | -$117,989,602 | $56.90 | 414 |
| 2022 Q3 | 131,997,507 | $5,220,452,246 | +$129,179,246 | $39.54 | 345 |
| 2022 Q2 | 128,322,139 | $5,647,663,757 | +$24,849,414 | $44.00 | 359 |
| 2022 Q1 | 128,337,653 | $5,115,592,058 | -$42,336,732 | $39.88 | 298 |
| 2021 Q4 | 129,389,920 | $5,202,313,554 | -$77,902,534 | $40.21 | 314 |
| 2021 Q3 | 130,048,093 | $5,289,784,296 | +$44,615,821 | $40.68 | 316 |
| 2021 Q2 | 129,727,357 | $5,890,257,760 | -$85,620,767 | $45.41 | 309 |
| 2021 Q1 | 132,146,550 | $5,510,245,951 | -$141,977,795 | $41.69 | 329 |
| 2020 Q4 | 136,300,724 | $5,821,984,170 | +$126,547,922 | $42.71 | 335 |
| 2020 Q3 | 133,950,846 | $3,522,042,268 | -$34,152,841 | $26.28 | 262 |
| 2020 Q2 | 135,245,376 | $3,623,665,867 | +$159,039,078 | $26.81 | 256 |